@article{003993b6e4a0487ebb1f82763465e3e0,
title = "Mesenchymal stem cells participate in oral mucosa carcinogenesis by regulating T cell proliferation",
abstract = "Recent evidences suggested that Mesenchymal stem cells (MSCs) may be involved in tumor formation by modulating of the tumor microenvironment, but it is still unclear the potential of MSCs in the malignant transformation of oral mucosa. Using a chemically-induced oral carcinogenesis model by 4-nitroquinoline-1-oxide (4NQO), we generated precancerous lesions and cancerous lesions in the oral cavity of rats. Flow cytometric analysis on lesions derived single cell suspension revealed an increase in the proportion of MSCs and a decreased proportion of T cell during oral mucosa malignancy. Moreover, MSCs showed increased immunosuppression capacity on T cell proliferation during mucosa malignancy. At last, we demonstrated that higher frequency of lesions resident MSCs was correlated with more Ki67 expression in the lesion, which indicated higher cellular proliferative status in the lesions. Our study demonstrated that MSCs may play an important role in oral mucosa malignant transformation through regulating T cell proliferation.",
keywords = "4-Nitroquinoline-1-oxide, Immunomodulation, Mesenchymal stem cell, Oral cancer, Oral potential malignant disorder, Stemness",
author = "Yichen Chen and Xi Wang and Juan Fang and Jingjing Song and Da Ma and Liqun Luo and Bailin He and Juan Xia and Lui, {Vivian Wai Yan} and Bin Cheng and Zhi Wang",
note = "Funding Information: We acknowledge support from the National Natural Science Foundation of China, China (No.81772896, 81472524, 81630025, 81602383), support from Science and Technology Program of Guangzhou, China (201704020102), supports from Research Grant Council, Hong Kong (#17114814, #17121616, General Research Fund), (Theme-based Research Scheme: T12-401/13-R to VWYL), and the Start-up Fund from the School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong; and the Hong Kong Cancer Fund. Funding Information: We acknowledge support from the National Natural Science Foundation of China , China (No. 81772896 , 81472524 , 81630025 , 81602383 ), support from Science and Technology Program of Guangzhou , China ( 201704020102 ), supports from Research Grant Council, Hong Kong (# 17114814 , # 17121616 , General Research Fund), (Theme-based Research Scheme: T12-401/13-R to VWYL), and the Start-up Fund from the School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong , Hong Kong; and the Hong Kong Cancer Fund . Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2019",
month = jan,
doi = "10.1016/j.clim.2018.12.001",
language = "English (US)",
volume = "198",
pages = "46--53",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
}